Peanut butter at breakfast may tame blood sugar and sharpen the mind

NCT ID NCT07714096

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks at whether eating a daily serving of peanut butter at breakfast can improve blood sugar control, thinking skills, and heart health in middle-aged adults with prediabetes. Participants will either add peanut butter to their first meal or stick with their usual diet for 12 weeks. Researchers will measure changes in HbA1c, fasting glucose, and other markers of metabolic and cognitive health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
peanut butter
What this could lead to
If it works, this could point toward a simple dietary change to help manage prediabetes and reduce heart disease risk.
What could go wrong
This is a small, early-stage trial with only 56 participants, so results may not apply to everyone. The effect may be modest or not significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40-65 years * BMI 25 to 40 kg/m2 * HbA1c 5.7-6.4% * Low habitual intake of peanut butter (\<0.5 Tablespoons/day on average) * Have a smartphone device or be willing to use one provided by the study Exclusion Criteria: * Hemoglobin \<13.2 g/dL for men or \< 11.7 g/dL for women at screening * Fasting triglycerides \>350 mg/dL at screening * LDL-cholesterol ≥190 mg/dL assessed by the Martin-Hopkins equation at screening * ≥10% change in body weight within the 6 months prior to enrollment * Blood pressure \>140/90 mmHg at screening * Diagnosed type 1 or type 2 diabetes * Takes any (prescription or over-the-counter) anti-hypertensive, lipid-lowering, glucose-lowering or body weight altering drugs * Intake of supplements that affect the outcomes of interest (i.e., lipids, blood pressure, glucose, body weight, and microbiome) and are unwilling to cease during the study period. * Unwilling to refrain from starting to take any supplements, vitamins, nutritional products, or health foods that are not prescribed by a doctor for the duration of the study * Self-reported history of diagnosed liver, kidney, or autoimmune disease * Self-reported history of a prior cardiovascular event (e.g., stroke, heart attack) * Self-reported history of diagnosed neurological disease (e.g. Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis) * Current pregnancy or intention of pregnancy within the next 12 months * Lactation within the prior 6 months * Peanut allergy/intolerance/sensitivity/dislike * Antibiotic use within the prior four weeks * Oral steroid use within the prior four weeks * Use of tobacco or nicotine-containing products within the past 6 months * History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence) * Participation in another clinical trial within 60 days of baseline * Currently following a restricted or weight-loss diet * Prior bariatric surgery * Intake of \>14 alcoholic drinks/week and/or not willing to avoid alcohol consumption for 48 hours prior to test visits * Does not speak and/or understand English * Unwilling to refrain from donating blood and/or plasma during the study * Weight \<110 lb * Unwilling to contact study staff before enrolling in other health-related research and avoid participating in any research that may interfere with this study * For individuals taking thyroid medication: abnormal thyroid stimulated hormone (TSH) concentration, or change in dose of thyroid medication within the last 6 months * Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Pennsylvania State University

    University Park, Pennsylvania, 16802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.